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This paper describes patient characteristics, including Ebola viral load, associated with mortality in a Médecins
Sans Frontières Ebola case management centre (CMC).
Out of 780 admissions between June and October 2014, 525 (67%) were positive for Ebola with a known outcome.
The crude mortality rate was 51% (270/525). Ebola viral load (whole-blood sample) data were available on 76% (397/
525) of patients. Univariate analysis indicated viral load at admission, age, symptom duration prior to admission,
and distance traveled to the CMC were associated with mortality (P < .05). The multivariable model predicted mor-
tality in those with a viral load at admission greater than 10 million copies per milliliter (P < .05, odds ratio >10),
aged ≥50 years (P = .08, odds ratio = 2) and symptom duration prior to admission less than 5 days (P = .14). The
presence of confusion, diarrhea, and conjunctivitis were signiﬁcantly higher (P < .05) in Ebola patients who died.
These ﬁndings highlight the importance viral load at admission has on mortality outcomes and could be used to
cohort cases with viral loads greater than 10 million copies into dedicated wards with more intensive medical sup-
port to further reduce mortality.
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The current Ebola virus disease (EVD) outbreak in
West Africa [1] is now the largest yet documented,
with the countries of Guinea, Liberia, and Sierra
Leone most affected [2]. The World Health Organiza-
tion (WHO) declared the outbreak a public health
emergency of international concern on 8 August 2014
[3]. The transmission of EVD via infected body ﬂuids
occurs predominantly in 3 settings: (1) family/commu-
nity through contact with an infected individual or con-
taminated fomites; (2) funerals, due to touching
deceased infected bodies; and (3) nosocomial, via the
absence of appropriate infection control measures in
healthcare settings [4–7].
Sierra Leone has a population of just under 6 million, a
life expectancy of 45 years, and an expenditure on health
per capita of 205 international dollars [8]. The district of
Kailahun is located in the east of the country, and in
response to a number of cases of EVD, Médecins Sans
Frontières (MSF) constructed a 50-bed Ebola Case Man-
agement Centre (CMC) near Kailahun city (capital of the
district), which opened on 26 June 2014. The capacity of
this centerwas further increased to 80 beds inAugust 2014
due to the increased number of EVD cases in the district.
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MSF has been involved in the control of many past EVD out-
breaks in central Africa and has developed established guide-
lines that are regularly referenced by other nongovernmental
organizations [9, 10]. The Kailahun CMC (KCMC) [11] is con-
structed according to these guidelines and is divided into low-
and high-risk zones. The low-risk zone comprises medical and
nursing administrative tents, laundry area, storage tents, water
chlorination points, and other facilities to support the high-risk
zone. Within the high-risk zone are located the triage tent; sus-
pect, probable, and conﬁrmed cases tents; morgue; and high-
risk waste area. Personal protective equipment must be worn
at all times in the high-risk zone.
Patients are initially assessed in the triage area, and if they ful-
ﬁll the WHO case deﬁnition criteria [12] are relocated to the
suspect or probable tents as appropriate to await an EVD poly-
merase chain reaction (PCR) test on a whole-blood sample.
When this test is positive, the patient is transferred to the con-
ﬁrmed tents, while a negative result allows the patient to be dis-
charged if the duration of symptoms has been 72 hours or
greater. When a suspect/probable patient has a negative PCR re-
sult but symptom duration of less than 72 hours, a repeat PCR
test is performed at 72 hours or more of symptoms to rule out a
false-negative result [10, 13]. A proportion of patients assessed
in the triage area were referred from government health centers.
This proportion is unknown, as only the home address is re-
corded on the patient register.
This paper describes the characteristics associated with mor-
tality among EVD-positive cases admitted to the KCMC
between June and October 2014.
METHODS
Data Collection
A retrospective cohort study of all patients admitted to the KCMC
between 26 June and 12 October 2014 was carried out. A patient
register, constructed usingMicrosoft Excel 2010, was on site at the
KCMC. Each patient was designated a unique MSF identiﬁcation
number (MSF ID). Clinical, laboratory, and epidemiological data
were collected on all admitted cases and stored in a secure format
on the register. Epidemiological information recorded included
age, gender, address, distance traveled to KCMC, occupation,
symptom duration prior to admission, length of stay, contact his-
tory, and patient outcome (classiﬁed as cured, death due to EVD,
death not due to EVD, defaulter, and not a case). Clinical and lab-
oratory data were restricted to the constellation of symptoms pre-
sent on admission and the EVD viral load (fromwhole-blood and
blood-swab samples, respectively).
When it was not possible for medical staff to obtain a whole-
blood sample through venesection, a blood-swab sample from a
punctured skin site was taken as an alternative sample in con-
sultation with the onsite laboratory. The resulting viral load val-
ues from positive blood swabs may not be directly comparable
to the viral load values from positive whole-blood venous spec-
imens, as the 2 forms of sampling have not previously been val-
idated against one another. Therefore, viral load blood-swab
values were excluded from the primary analysis.
Data Matching
Laboratory data were initially maintained on a separate register
to the patient register, and these data were subsequently merged
using the MSF ID. The cycle threshold (CT) result from the ﬁrst
EVD PCR whole-blood test carried out on or after admission
was used as the measure of viral load at admission. Of note, if
the ﬁrst whole blood EVD PCR test was performed greater than
5 days postadmission, then the result was not considered to rep-
resent the viral load at admission. Similar matching was per-
formed for blood-swab results.
Laboratory Analysis
Samples were received by the onsite laboratory from the KCMC
medical staff and inactivated using a recognized method [14] in-
side a ﬂexible ﬁlm negative-pressure isolator followed by RNA
extraction and puriﬁcation. Quantitative reverse-transcription
PCR (qRT-PCR) assays targeting the L and NP genes were
used to detect the presence of Zaire Ebola virus using Lightcy-
cler RNA Master Hydrolysis reagents (Roche, Laval, PQ)
according to manufacturer’s instructions. Assays were per-
formed on the Lightcycler Nano platform (Roche). Primary
testing focused on EVD diagnosis using cut-off cycle threshold
(CT) values for positive, equivocal, and negative of <36, 36.1–40,
and >40, respectively. The lower the CT value, the higher the
Ebola viral load and vice versa. The assays detected EVD at
10 genome equivalents (g.e.)/reaction. For differential diagnos-
tics when requested, the laboratory offered qRT-PCR tests for
Lassa virus [15] and Plasmodium species [16]. As an internal
control for extraction and ampliﬁcation procedures, MS2
phage was added to each sample as previously described [17].
Statistical Analysis
We used Welch t test, Fisher exact test, or the Wilcoxon rank-
sum test, as appropriate, to determine the association between
mortality and the variables age, gender, occupation, the pres-
ence of gastrointestinal hemorrhage, the number of days be-
tween symptom onset and admission, whole-blood CT value
at admission, and distance traveled to the KCMC. All variables
with a P value <.1 in the univariate analysis were included in the
binary (survival vs death) multivariable logistic regression
model. Nonsigniﬁcant variables were eliminated in a stepwise
fashion. Kaplan–Meier methods were used to determine surviv-
al curves for various groups of patients, using the interval from
admission to death, with data censored at 36 days for survivors.
Survival according to age was examined using a scatter plot
and 5-year age categories to determine the most appropriate age
comparisons. Additionally, box-plots of whole-blood EVD PCR
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CT results among survivors and nonsurvivors were constructed to
determine the most appropriate dichotomous CT comparisons.
All statistical tests were 2-tailed, with a P value of less than
.05 considered to indicate statistical signiﬁcance. All analyses
were performed using R software, version 3.0.2.
RESULTS
A total of 780 admissions to the KCMC occurred between
26 June and 12 October 2014. Of these, 525 (67%) had PCR-
conﬁrmed EVD with a known outcome (survived or death due
to EVD). The remaining 255 (33%) admissions were classiﬁed
as not a case (232, 91%), current admission awaiting outcome
(13, 5%), non-EVD death (7, 3%), and defaulter (3, 1%).
Regarding EVD cases with a known outcome (n = 525), the
overall median age was 27 years (interquartile range [IQR],
16–40) and for males and females it was 28 (IQR, 18–40) and
27 (IQR, 15–38) years, respectively. Males represented 272
(52%) cases. The median time intervals from symptom onset
to admission, admission to death, and admission to survival
were 5 days (IQR, 3–7), 4 days (IQR, 2–6), and 13 days (IQR,
10–18), respectively. The overall case fatality rate of 51% for
the KCMC had a weekly ﬂuctuation (by week of admission),
ranging from 24% to 85% during the study period (Figure 1).
The frequency of symptoms between EVD-positive patients
who died and survived were compared, and diarrhea, confusion,
and conjunctivitis were found to be statistically different (P <
.05) between the 2 outcomes (Supplementary Table 1).
Among the 525 EVD admissions with a known outcome, 128
(24%) did not have a CT value from a whole-blood sample
recorded on the laboratory register. A further 51 (10%) did
not have whole-blood EVD PCR test results recorded within
5 days of admission, and later tests were not considered relevant
as a measure of viral load at admission. The remaining 346
(66%) admissions had CT values available from whole-blood
samples taken within 5 days of admission, of which 319
(61%) were taken within 1 day of admission (Supplementary
Figure 1). The median time from admission to death for those
with an admission CT < 25 and ≥25 was 4 days (IQR, 2–6) and
4 days (IQR, 3–5), respectively. An EVD CT value of 25 is
equivalent to a viral load of 1.28 × 10⁷ copies per milliliter of
blood.
A readmission to the KCMC occurs when a patient is initially
discharged as not having EVD and then subsequently readmit-
ted to the KCMC after a variable period of time to be reassessed
for EVD. The 525 EVD-positive admissions with known out-
come comprised 511 (97%) primary admissions and 14 (3%)
readmissions, resulting in 270 (51%) deaths (262 primary ad-
missions and 8 readmissions) and 255 survivors (244 primary
admissions and 11 readmissions) (Supplementary Figure 2).
A total of 31 healthcare workers were admitted to the KCMC
with positive EVD PCR of which 20 died, 9 survived, and 2 were
transferred to another health facility. The outcome of those
transferred was not known. The overall mortality rate for
healthcare workers with a known outcome was 69% (20/69).
Kailahun district is divided into 14 chiefdoms, and the Kai-
lahun MSF CMC is located in the chiefdom of Luawa. Of the
525 conﬁrmed cases with known outcome, 326 (62%) came
from the district of Kailahun, with the remaining originating
from districts across the rest of the country (Supplementary
Figure 1. Fluctuation of crude fatality rate by week of admission (26–42), Kailahun Ebola Case Management Centre, Sierra Leone, 2014.
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Figure 3 and 4). Address information was available for 505
(96%) cases, and 181 (36%) had traveled greater than 100 km
to reach the KCMC. The overall crude mortality for those
who traveled less than and greater than 100 km was 58%
(187/324) and 40% (73/181), respectively (P < .001). Addition-
ally, Figure 2 presents the relationship between distances trav-
eled, interval between symptom onset and admission, and
overall crude mortality rate.
A number of variables between survivors and nonsurvivors
were shown to be signiﬁcantly (P < .05) different among the
525 EVD-positive patients with known outcomes, including
age, whole-blood CT value at admission, interval between
symptom onset and admission, length of stay, and distance trav-
eled to KCMC (Table 1). Of note, median interval between
symptom onset and admission was longer for survivors (6
days) than nonsurvivors (4 days).
Multivariable Logistic Regression Model
The selected logistic regression model adjusted for age, whole-
blood CT value at admission, and time from symptom onset
to KCMC admission. The parameter estimates, P values, and
odds ratios are shown in Table 2. All other variables (both clin-
ical and epidemiological), including healthcare worker status
and distanced traveled to the KCMC, did not contribute to
the multivariable model and thus were removed. The chosen
model indicates that whole-blood CT value on admission was
the most signiﬁcant predictor of mortality in the dataset with
age (P = .08) and duration of symptoms prior to admission
(P = .14) being less so. The receiver operating characteristic
value for the preferred model was 0.82. The effect of
admission whole-blood CT value on survival is represented
by a Kaplan–Meier curve in Figure 3. The survival curve of
EVD-positive infants approximates that of adults aged >50
years (Figure 4), while cases aged between 1 and 50 years dem-
onstrate better survival outcomes when compared with the
prior 2 age groups.
Number of Whole-Blood EVD PCR Tests Per Patient
Of the 525 EVD-positive admissions with known outcome, 150
(29%) had 2 or more whole-blood PCR tests performed (a min-
imum of several days apart) during their admission. Interesting-
ly, the overall mortality rate for this group of patients was 9%
(13/150) as opposed to 69% (257/375) for the remaining admis-
sions within the group. Furthermore, for those patients with 2
or more whole-blood EVD PCR tests performed during the
same admission, the mortality rate when the second PCR test
Figure 2. Mortality rate and interval (days) between symptom onset and
admission by distance traveled to Kailahun CMC. Abbreviation: CMC, case
management centre.
Table 1. Differences in Characteristics Between EVD-Positive Patients Who Died and Survived, Kailahun Ebola Case Management
Centre, Sierra Leone, 2014
Characteristic Survivor (n = 255) Death (n = 270) P Value
Median CT value at admission (IQR) 31 (25–34) 22 (20–25) 2.20 × 10−16
Median length of stay, days (IQR) 13 (10–18) 4 (2–6) 2.20 × 10−16
Median distance traveled to KCMC, km (IQR) 49 (28–160) 38 (27–113) 8.00 × 10−05
Median interval between symptom onset and admission, days (IQR) 6 (3–9) 4 (3–7) .0001
Median age, years (IQR) 25 (14–35.5) 30 (19–42.25) .0007
Healthcare worker, no. (%) 9 (3.5) 20 (7.4) .0808
Hemorrhage, no. (%) 1 10 .1703
Male : female ratio 131:124 141:129 .9145
Abbreviations: CT, cycle threshold; EVD, Ebola virus disease; IQR, interquartile range; KCMC, Kailahun CMC.
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had a lower CT (higher viral load) than the ﬁrst was 58% (7/12),
while the mortality rate for those with a second PCR test with
the same or higher CT (lower viral load) than the ﬁrst was 4%
(6/138). This difference in mortality rate associated with the CT
value of the second whole-blood sample was statistically signiﬁ-
cant (P < .05).
Nonwhole-Blood Sample Types (Blood Swabs)
A total of 71 admissions had blood swabs performed by medical
staff of which 31 (44%) were EVD positive, had a CT value, age,
interval between symptom onset and admission, and known
outcome recorded and were performed within 5 days of admis-
sion to the KCMC (Supplementary Figure 5). The whole-blood
multivariable logistic regression model was used to calculate the
expected number of deaths for blood-swab cohorts with a CT
<25 and ≥25. A χ2 test was applied. The null hypothesis stated
that the parameters from the whole-blood multivariable logistic
regression model could be applied to blood swab results to pre-
dict mortality. The test failed to reject the null hypothesis
(Table 3), which may indicate that the whole-blood model
could be used for blood swabs to predict mortality (although
the result should be treated with caution as the sample size
was small). Blood swabs with a CT value <25 were a closer ﬁt
to the whole-blood model than those ≥25 (z² of 0.16 and 3.39,
respectively).
DISCUSSION
Various EVD case fatality rates (CFRs) have been reported dur-
ing this outbreak [18–20] and our study has shown a favorable
rate of 51% among conﬁrmed cases. There are many reasons
why certain centers have lower EVD CFRs than others,




Intercept −0.9759 .0004 0.3769 .2167–.6358
Age ≥50 y 0.7644 .0791 2.1477 .9278–5.1602
CT <25 at
admission





−0.4354 .1404 0.6470 .3632–1.1602
Abbreviations: CI, confidence interval; CT, cycle threshold.
Figure 3. Kaplan–Meier curve of the probability of survival among pa-
tients with EVD according to CT value. Abbreviations: CT, cycle threshold;
EVD, Ebola virus disease.
Figure 4. Kaplan–Meier curve of the probability of survival among pa-
tients with EVD according to age. Abbreviation: EVD, Ebola virus disease.











1 ≥25 21 10 6 0.27 3.39
2 <25 10 9 8 0.79 0.16
Total 31 19 14 0.44 3.54
N = 31; crude mortality rate = 61% (19/31).
Critical value for χ2 test = 3.84.
Abbreviation: CT, cycle threshold.
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including: the sickest EVD patients dying before they reach the
CMC; well-established health promotion activities in the com-
munity, allowing patients to avail of medical support as early as
possible; and the availability of professional care according to
designated protocols. It is also notable that within the KCMC,
the weekly CFR varied between 24% and 85% (by admission
week) during the study period. The reasons for this variation
are unclear as all patients received standardized medical care
during their admission according to MSF guidelines. Addition-
ally, inexperienced staff are always paired with more senior staff
to ensure that the level of care provided is consistent throughout
the life of the KCMC. These measures are of particular impor-
tance in an environment where there is a high turnover of staff
due to the physical and emotional burden of the workload.
It is noteworthy that the interval between symptom onset and
admission was longer (6 days) for survivors than nonsurvivors
(4 days). This is a counterintuitive ﬁnding and is potentially ex-
plained by those more likely to die, due to the longer interval
between symptom onset and admission, having done so prior
to admission (selection bias). However, in the multivariable re-
gression model, the interval between symptom onset and ad-
mission was not signiﬁcant (P = .14) and age was marginally
signiﬁcant (P = .08). The most inﬂuential predictor of mortality
within the multivariable regression model was whole-blood CT
value at admission (P = 9.7 × 10−16) with an odds ratio of 10.8
in favor of mortality when the CT value was <25 (equivalent to
107 viral copies per mL or greater). This ﬁnding could be used in
the ﬁeld to cohort patients with CT values of <25 into dedicated
wards where they could receive enhanced medical support and
palliative care if resources allow due to their much-increased
risk of death. These high-risk patients could also be prioritized
for experimental treatments under strict ethical protocol. The
increased risk of death with higher Ebola viral loads document-
ed here supports the ﬁndings in a previous outbreak of Ebola in
Uganda in 2000 [21, 22].
The ﬁnding that a follow-up improving CT value resulted in a
mortality rate of 4% versus 58% for a deteriorating one is note-
worthy. The very fact that an EVD patient has survived long
enough to undergo a follow-up phlebotomy procedure indicates
they have an overall improved chance of survival regardless of
the viral load at admission.
Sometimes, in the ﬁeld it is difﬁcult for medical staff to obtain
a whole-blood sample from patients with poor venous access. In
such cases, the skin is punctured under aseptic technique and a
blood swab is taken. This procedure is easier and safer for staff
to perform; however, it was unknown how well a CT value from
a blood swab correlates with that from a whole-blood sample.
Although the sample size was small, our results indicate that
a blood swab, particularly with a CT value <25, may be used
to predict mortality, as we found no evidence that the results
do not approximate that of whole-blood samples. We propose
that further monitoring of blood swab results be undertaken to
substantiate these early ﬁndings. This is of potential impor-
tance, as it would provide staff with a safe, alternative procedure
for obtaining a blood sample if they fail to attain a whole-blood
sample through phlebotomy.
The mapping of conﬁrmed cases indicates that a large pro-
portion stem from districts outside Kailahun, as far away as
the capital, Freetown. This has important implications for con-
trol of the EVD outbreak at a national level, as the transfer of
large numbers of cases across the country by various modes
of transport could potentially facilitate the unintentional spread
of the virus. The large number of admissions originating outside
Kailahun was associated with the lack of operational CMCs in
other districts of Sierra Leone at that time. Notably, patients
who traveled greater than 100 km to reach the KCMC had a
lower mortality rate than those who journeyed less than 100
km. This paradoxical result could be explained by the possibility
that for the cohort who traveled greater than 100 km, cases with-
in it who had a low chance of survival already died before reach-
ing the KCMC, therefore causing an artiﬁcially low crude
mortality rate for this group within the KCMC.
There are many challenges regarding the accurate collection
of epidemiological, clinical, and laboratory data in the ﬁeld set-
ting inWest Africa, including heavy workload, difﬁculty obtain-
ing information from patients due to language barriers, and lack
of an information technology infrastructure to allow healthcare
professionals to record data electronically at point of patient
contact. These factors contributed to the incomplete data pre-
sented in our results, which is an obvious limitation of the
study. Another drawback was that the study included no clinical
data while cases were inpatients in the KCMC. This information
was collected on individual patient paper records but was not
transcribed electronically to the patient register.
This study documents the importance of viral load at admis-
sion on predicting mortality in a large MSF Ebola case manage-
ment center in a remote jungle region of Eastern Sierra Leone.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
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data are the sole responsibility of the authors. Questions or messages regard-
ing errors should be addressed to the author.
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